PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Thursday, February 29, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the fourth quarter 2023. The interim report is available as an attached document and on the company website (www.biosergen.net)
Summary of the Interim Report for Q4 2023
2023 2022 2023 2022
TSEK Oct-Dec Oct-Dec Jan-Dec Jan-Dec
Other income 1.315 1.964 9.378 5.183
Profit/loss before depreciation (EBITDA) -6.662 -12.491 -27.266 -39.987
Operating profit/loss befor net financials -6.662 -12.491 -27.037 -39.987
Net financials 193 87 229 109
Netprofit/loss for the period -6.469 -12.432 -27.037 -39.906
Earnings per share (SEK) -0,13 -0,40 -0,53 -1,28
Highlights during Q4 2023- December 12, Biosergen's Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy
- February 12, Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.
- January 30, Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan
- January 12, Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor
The Financial report can be found on our website: https://biosergen.net/investors/filings